To report any concerns or inaccuracies, please contact us at [email protected]. The post COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024 appeared first on InvestorPlace.

Shares of Cocrystal Pharma (NASDAQ:COCP) plunged 40% Tuesday after the company said it plans to extend a Phase 2a challenge study for its influenza drug candidate CC-42344 due to an unexpectedly ...

and streamline your search for investment opportunities using Tipranks' Stock Screener The latest update is out from Cocrystal Pharma ( (COCP)). Cocrystal Pharma announced positive interim results ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

YTD Price Performance: 88.73% Average Trading Volume: 30,560 Technical Sentiment Consensus Rating: Hold Current Market Cap: $33.06M See more insights into COCP stock on TipRanks’ Stock Analysis ...

Data indicates a favorable safety and tolerability profile for CC-42344, with no serious adverse events or drug-related discontinuations reported. Extension of enrollment in the Phase 2a study ...

YTD Price Performance:-2.59% Average Trading Volume: 42,998 Technical Sentiment Consensus Rating: Hold Current Market Cap: $24.42M For a thorough assessment of COCP stock, go to TipRanks’ Stock ...

BOTHELL, Wash. - Cocrystal Pharma, Inc. (NASDAQ: COCP), a clinical-stage biotechnology company, announced today the successful completion of a Phase 1 study's single-ascending dose... ByInvesting ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This page features the latest news about the Cocrystal Pharma stock. Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of ...